NEW YORK (GenomeWeb News) – Canadian diagnostic test developer Miraculins said today that it has partnered with Inverness Medical Innovations to commercialize Miraculins' suite of biomarkers for preeclampsia.

Under the collaborative research and option agreement, Inverness, through its Biosite division, will develop tests for Miraculins' panel of 35 biomarkers involved in placenta development and the occurrence of preeclampsia, a potentially fatal pregnancy complication.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.